LALPATHLAB - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.2
| Stock Code | LALPATHLAB | Market Cap | 22,193 Cr. | Current Price | 1,325 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 41.4 | Book Value | 140 ₹ | Dividend Yield | 0.91 % | ROCE | 31.2 % |
| ROE | 25.4 % | Face Value | 10.0 ₹ | DMA 50 | 1,403 ₹ | DMA 200 | 1,461 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 37.8 | MACD | -20.3 | Volume | 1,07,480 | Avg Vol 1Wk | 2,16,622 |
| Low price | 1,176 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.17 | Debt to equity | 0.06 |
| 52w Index | 25.1 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 36.9 |
📊 Dr. Lal PathLabs (LALPATHLAB) has strong fundamentals with high ROCE (31.2%) and ROE (25.4%), supported by a debt-light balance sheet. However, technical indicators are weak (RSI 37.8, MACD -20.3, price below 50 & 200 DMA). Valuation is slightly stretched with P/E (41.4) above industry average (36.9). This makes it a moderately good candidate for swing trading with cautious positioning.
💡 Optimal Entry Price: Around ₹1,300–1,325, near support levels.
📈 Exit Strategy (if already holding): Consider exiting near ₹1,400–1,450 if recovery occurs, or cut losses if price falls below ₹1,280 decisively.
Positive
- Strong ROCE (31.2%) and ROE (25.4%) indicate efficient capital use.
- Debt-to-equity ratio of 0.06 shows virtually debt-free balance sheet.
- Dividend yield of 0.91% provides steady income.
- EPS of ₹30.8 reflects solid earnings base.
- Quarterly PAT of ₹113 Cr. remains strong despite slight decline.
Limitation
- P/E (41.4) is higher than industry average (36.9), suggesting premium valuation.
- PEG ratio of 3.17 indicates expensive valuation relative to growth.
- Price trading below both 50 DMA (1,403) and 200 DMA (1,461), confirming bearish trend.
- Quarterly PAT declined from ₹146 Cr. to ₹113 Cr., showing earnings pressure.
Company Negative News
- FII holdings decreased (-1.57%), showing reduced foreign investor confidence.
- Technical weakness with RSI near oversold zone and MACD negative.
Company Positive News
- DII holdings increased (+0.98%), reflecting strong domestic institutional support.
- Quarterly profit variation (+7.24%) shows resilience despite decline in absolute PAT.
Industry
- Industry P/E at 36.9 is slightly lower than Lal PathLabs’, suggesting the stock trades at a premium.
- Diagnostics sector remains defensive and growth-oriented, supported by rising healthcare demand and preventive testing trends.
Conclusion
⚖️ Lal PathLabs is fundamentally strong but technically weak, with high valuation and bearish momentum. Swing traders may cautiously enter near support (~₹1,300–1,325) and exit near resistance (~₹1,400–1,450). Conservative traders should wait for stronger technical signals before entering.